3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Interventions
fludarabine phosphate
31
Peripheral Blood Stem Cell Transplantation
26
Cyclophosphamide
25
Mycophenolic Acid
24
Whole-Body Irradiation
23
Busulfan
21
Tacrolimus
19
Cyclosporine
19
Antilymphocyte Serum
14
Methotrexate
13
Imatinib Mesylate
12
Cord Blood Stem Cell Transplantation
11
Melphalan
10
Dasatinib
10
Cyclosporins
8
nilotinib
7
Methylprednisolone
7
Etoposide
7
Radiotherapy
6
Filgrastim
6
Alemtuzumab
6
Sirolimus
5
thymoglobulin
4
sargramostim
4
bosutinib
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
fludarabine
3
Thiotepa
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, Myeloid, Chronic-Phase
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts